291 related articles for article (PubMed ID: 26014298)
1. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Taphoorn MJ; Henriksson R; Bottomley A; Cloughesy T; Wick W; Mason WP; Saran F; Nishikawa R; Hilton M; Theodore-Oklota C; Ravelo A; Chinot OL
J Clin Oncol; 2015 Jul; 33(19):2166-75. PubMed ID: 26014298
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Chinot OL; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Carpentier AF; Hoang-Xuan K; Kavan P; Cernea D; Brandes AA; Hilton M; Abrey L; Cloughesy T
N Engl J Med; 2014 Feb; 370(8):709-22. PubMed ID: 24552318
[TBL] [Abstract][Full Text] [Related]
4. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
Sandmann T; Bourgon R; Garcia J; Li C; Cloughesy T; Chinot OL; Wick W; Nishikawa R; Mason W; Henriksson R; Saran F; Lai A; Moore N; Kharbanda S; Peale F; Hegde P; Abrey LE; Phillips HS; Bais C
J Clin Oncol; 2015 Sep; 33(25):2735-44. PubMed ID: 26124478
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
Osoba D; Brada M; Yung WK; Prados M
J Clin Oncol; 2000 Apr; 18(7):1481-91. PubMed ID: 10735896
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N
Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Gilbert MR; Dignam JJ; Armstrong TS; Wefel JS; Blumenthal DT; Vogelbaum MA; Colman H; Chakravarti A; Pugh S; Won M; Jeraj R; Brown PD; Jaeckle KA; Schiff D; Stieber VW; Brachman DG; Werner-Wasik M; Tremont-Lukats IW; Sulman EP; Aldape KD; Curran WJ; Mehta MP
N Engl J Med; 2014 Feb; 370(8):699-708. PubMed ID: 24552317
[TBL] [Abstract][Full Text] [Related]
9. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ;
Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986
[TBL] [Abstract][Full Text] [Related]
10. Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Pollom EL; Fujimoto D; Wynne J; Seiger K; Modlin LA; Jacobs LR; Azoulay M; von Eyben R; Tupper L; Gibbs IC; Hancock SL; Li G; Chang SD; Adler JR; Harsh GR; Harraher C; Nagpal S; Thomas RP; Recht LD; Choi CYH; Soltys SG
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):123-130. PubMed ID: 28586949
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.
Minniti G; Scaringi C; Baldoni A; Lanzetta G; De Sanctis V; Esposito V; Enrici RM
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):285-91. PubMed ID: 23642624
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
Lou E; Peters KB; Sumrall AL; Desjardins A; Reardon DA; Lipp ES; Herndon JE; Coan A; Bailey L; Turner S; Friedman HS; Vredenburgh JJ
Cancer Med; 2013 Apr; 2(2):185-95. PubMed ID: 23634286
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
Saran F; Chinot OL; Henriksson R; Mason W; Wick W; Cloughesy T; Dhar S; Pozzi E; Garcia J; Nishikawa R
Neuro Oncol; 2016 Jul; 18(7):991-1001. PubMed ID: 26809751
[TBL] [Abstract][Full Text] [Related]
15. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Taphoorn MJB; Dirven L; Kanner AA; Lavy-Shahaf G; Weinberg U; Taillibert S; Toms SA; Honnorat J; Chen TC; Sroubek J; David C; Idbaih A; Easaw JC; Kim CY; Bruna J; Hottinger AF; Kew Y; Roth P; Desai R; Villano JL; Kirson ED; Ram Z; Stupp R
JAMA Oncol; 2018 Apr; 4(4):495-504. PubMed ID: 29392280
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
Lai A; Tran A; Nghiemphu PL; Pope WB; Solis OE; Selch M; Filka E; Yong WH; Mischel PS; Liau LM; Phuphanich S; Black K; Peak S; Green RM; Spier CE; Kolevska T; Polikoff J; Fehrenbacher L; Elashoff R; Cloughesy T
J Clin Oncol; 2011 Jan; 29(2):142-8. PubMed ID: 21135282
[TBL] [Abstract][Full Text] [Related]
17. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Armstrong TS; Wefel JS; Wang M; Gilbert MR; Won M; Bottomley A; Mendoza TR; Coens C; Werner-Wasik M; Brachman DG; Choucair AK; Mehta M
J Clin Oncol; 2013 Nov; 31(32):4076-84. PubMed ID: 24101048
[TBL] [Abstract][Full Text] [Related]
18. Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
Clement PMJ; Dirven L; Eoli M; Sepulveda-Sanchez JM; Walenkamp AME; Frenel JS; Franceschi E; Weller M; Chinot O; De Vos FYFL; Whenham N; Sanghera P; Looman J; Kundu MG; Peter de Geus J; Nuyens S; Spruyt M; Gorlia T; Coens C; Golfinopoulos V; Reijneveld JC; van den Bent MJ
Eur J Cancer; 2021 Apr; 147():1-12. PubMed ID: 33601293
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Taphoorn MJ; Stupp R; Coens C; Osoba D; Kortmann R; van den Bent MJ; Mason W; Mirimanoff RO; Baumert BG; Eisenhauer E; Forsyth P; Bottomley A; ; ;
Lancet Oncol; 2005 Dec; 6(12):937-44. PubMed ID: 16321761
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
Grossman SA; Ye X; Piantadosi S; Desideri S; Nabors LB; Rosenfeld M; Fisher J;
Clin Cancer Res; 2010 Apr; 16(8):2443-9. PubMed ID: 20371685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
